pharma · COVID-19 · Poliomyelitis
Sinovac Research and
Sinovac Research and Development Co.,
SINOVAC BIOTECH (BANGLADESH) is a pharma organization headquartered in Dhaka, CN. Primary therapeutic focus areas include COVID-19, Poliomyelitis, Influenza, Hand, Foot and Mouth Disease, Varicella. NovaPharmaNews links
Dhaka, CN HQ
2022 Founded
9 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Dhaka, CN
- Founded
- 2022
- Employees
- 9
- Programs
- 115
- Drugs
- 54
- Patents
- 0
Tetravalent influenza vaccine developed by Sinovac Biotech Co.
Phase 3 · small molecule · Influenza
Tetravalent influenza vaccine developed by Sinovac Biotech Co. for Influenza is a Phase 3 program (small_molecule) at Sinovac Research and Development Co., with 1 ClinicalTrials.gov record(s).
Internal code PRO-QINF-3004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sinovac Research and Development Co.,
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Influenza
- Status
- active
- Trials
- 1